医药周报 20260208: 【国联民生医药】小核酸风口之上：四重催化密集 glmszqdatemark 医药行情回顾&分析&近期判断 行情回顾：当周（2.2-2.6）医药生物指数环比 0.14%，跑赢创业板指数和沪深 300 指数。在所有行业中，当周（2.2-2.6）医药涨跌幅排在第 14 位。医药在周一大 跌后，本周后面都是在演绎修复。结构上看，创新链条，A 股部分辨识度个股表 现不错，CRO 及部分上游条线表现较好。非创新药方面，消费医疗、中药也有一 定表现，表现从创新聚焦开始发散。医药成交总额 4755.06 亿元，沪深总成交额 为 119319.07 亿元，医药成交额占比沪深总成交额比例为 3.99%（2013 年以来 成交额均值为 7.09%）。 原因分析：医药整体不在市场重心，仍然是散点行情为主，同时内部切换特征也 比较明显，创新条线走发散逻辑，CRO 及部分上游表现较好。非创新药方面，受 市场整体消费表现较好带动，消费医疗部分表现相对较强，中药因政策刺激周五 表现较好，在行业普遍表现一般的状态下相对表现较好。近期重磅 BD，从走势反 馈角度，还在消化筹码，产业逻辑依旧强劲，核心标的逐步进入价值 ...

Core Insights - Oligonucleotide therapies are emerging as a significant breakthrough in the treatment of rare diseases, with over a dozen therapies approved globally and hundreds in clinical research, promising to benefit more patients in the future [1][14][15] Industry Developments - The global landscape has seen more than ten oligonucleotide therapies approved for rare diseases, providing new treatment options for conditions such as Amyotrophic Lateral Sclerosis (ALS), Duchenne Muscular Dystrophy (DMD), and Hemophilia [1][14] - There are currently over a hundred oligonucleotide therapies in clinical development targeting various rare diseases, including siRNA and antisense oligonucleotide (ASO) therapies [2][14] Recent Approvals and Innovations - In August, Ionis Pharmaceuticals received FDA approval for the LICA drug Dawnzera (donidalorsen) for preventing hereditary angioedema (HAE) attacks in patients aged 12 and older, marking it as the first RNA-targeted drug for HAE [4][18] - Ionis Pharmaceuticals and Sobi announced the approval of ASO drug Tryngolza (olezarsen) in the EU for treating genetically confirmed familial chylomicronemia syndrome (FCS) [4][19] - Alnylam Pharmaceuticals' siRNA therapy Amvuttra (vutrisiran) was approved by the FDA in March for treating patients with transthyretin amyloidosis with cardiomyopathy [5][19] Clinical Trial Progress - NS Pharma reported positive results from the long-term extension study of ASO therapy brogidirsen for DMD, showing effective exon 44 skipping and stable maintenance of motor function in patients [7][21] - RIBOMIC's umedaptanib pegol showed promising results in a Phase 2 trial for achondroplasia in children, with many patients experiencing improved height growth rates [7][21] - Ionis Pharmaceuticals' ASO therapy zilganersen demonstrated significant results in stabilizing walking speed in Alexander disease patients, with plans for a new drug application to the FDA in 2026 [8][22] WuXi TIDES Platform - WuXi TIDES has established an integrated solution for oligonucleotide and peptide therapies, covering custom synthesis, conjugation, process development, and CMC, facilitating the transition of innovative projects into clinical stages [1][11][26] - The platform offers comprehensive CRDMO services from drug discovery to commercial production, supporting high-throughput synthesis and custom synthesis for various oligonucleotides [11][26][27] Future Outlook - The company aims to continue leveraging its integrated CRDMO model to empower the development of various new drugs, including oligonucleotide therapies, to bring more effective treatments to patients [12][27]

Core Viewpoint - Alnylam Pharmaceuticals has transformed from a biotech company to a pharmaceutical leader, achieving a market capitalization of approximately $611 billion and aiming for a $100 billion valuation, driven by strong revenue growth and a robust pipeline of RNAi therapies [1][2][21]. Financial Performance - Alnylam's total revenue for the first three quarters of 2025 reached $2.617 billion, with product net revenue of $1.992 billion, marking a 67% year-over-year increase [4]. - The TTR product line saw an 85% revenue growth to $1.628 billion, primarily driven by Amvuttra and Onpattro [4]. - Alnylam's total revenue projections for 2025 have been raised to $2.95-3.05 billion, with TTR product revenue guidance adjusted to $2.475-2.525 billion [4]. Product Pipeline and Collaborations - Alnylam has over 15 projects in its pipeline, focusing on rare diseases, cardiovascular, metabolic, and neurological conditions, with Cemdisiran and Elebsiran in late-stage clinical trials [8][14]. - Strategic collaborations with companies like Novartis and Regeneron have accelerated product development and diversified revenue streams [6][7]. Key Products and Market Potential - Leqvio, a long-acting lipid-lowering drug developed in partnership with Novartis, is expected to exceed $1 billion in sales for the first time in 2025 [16]. - Zilebesiran, a novel hypertension treatment, is anticipated to revolutionize blood pressure management with a convenient dosing schedule [16][21]. Future Outlook - Alnylam's dual revenue model of product sales and licensing agreements supports short-term profitability while its innovative pipeline offers significant long-term growth potential [21]. - The company is well-positioned to achieve its goal of a $100 billion market valuation as it continues to launch impactful therapies [21].